MCL是一种典型高度表达CD20并对CD20靶向药物敏感的恶性淋巴瘤。本研究中,客观缓解率(ORR)达到100%,疗效持久,仅2例患者出现复发,且整体毒性可控。研究证实了自适应制备的LV20.19 CAR-T细胞可快速递送,疗效显著,且在复发/难治性套细胞淋巴瘤(...
研究评估了多种细胞内T细胞信号传导基序组合,最有效的duoCAR结构包含ICOS、OX40或CD27共刺激域,而不是CD28或4-1BB。 体外研究中,duoCAR-T细胞与单CAR-T细胞一样,以剂量依赖的方式裂解靶点阳性(target-positive)肿瘤细胞系。在体内研究中...
We designed a novel biologic, a CAR T Engager, that binds CD20 and displays the CD19 extracellular domain. This approach increases the apparent CD19 antigen density on CD19-positive/CD20-positive lymphoma cells, and prevents antigen-loss induced relapse, as CD19 bound to CD20 remains present ...
急性白血病细胞CD19和CD20表达比较.pdf,中国实验血液学杂志 ·943· 如“埘耐。,E甲P睹nPn缸f日册ld船fp删2∞5;13(6):943—947 文章编号(AnicleID):1009—2137(2(x)5)06—0943—05 ·论著· and betweenCDl9CD20 PatterIls Comparison Expression onAcuteL叫kemicCeUs N
CD19 is a double-edged sword, which functions as both positive and negative regulator in BCR signaling. • The biochemical basis of CD19 as BCR regulator is the recruitment of secondary signaling molecules like PI3K via its cytoplasmic tail, which may be inside or outside of lipid rafts, ...
Combinatorial CAR T-cell therapies have shown a clear advantage in preclinical studies of both solid and liquid tumors [13,14,15]. For example, the bivalent targeting of CD19/CD20 or CD19/CD22 in lymphoma and BL-ALL mitigated antigen escape in murine models [16,17,18,19]. Interestingly,...
We address this limitation through a first-in-human trial of bispecific anti-CD20, anti-CD19 (LV20.19) CAR T cells for relapsed, refractory B cell malignancies. Adult patients with B cell non-Hodgkin lymphoma or chronic lymphocytic leukemia were treated on a phase 1 dose escalation and ...
Targeting CD25-positive lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as single agent or in combination with targeted agents bioRxiv (2023) Google Scholar 26. C Tarantelli, E Gaudio, AJ Arribas PQR309 is a novel dual PI3K/mTOR inhibitor with preclinical antitumor activity...
We conducted this study to find more effective dual CAR19/20 T-cells to target B-cell lymphoma and prevent antigen loss leading to recurrence. In this study, we transduced CD19 and CD20 CARs into human T cells in parallel and compared parallel dual CAR19/20, single CAR, and tandem ...
ConclusionsCAR-T cell therapy not only played a role in the rescue treatment of relapsed and refractory patients, but also produced a surprising effect in the consolidation and maintenance of B-cell lymphoma. CD19 CAR-T cells might be more effective in the treatment of MRD positive B-cell lym...